Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Genesys/Takeda: Not Quite Validation for Cell Therapy

This article was originally published in Start Up

Executive Summary

After enduring years of investor and partner skepticism, cell therapy has finally gotten what should be its validating deal: Cell Genesys's $50-million-upfront worldwide alliance with Takeda for Phase III GVAX prostate. But none of the companies who discussed licensing the product focused on the fact that it is a cellular therapy , regarding it as a prostate cancer treatment that happens to be a cellular therapy. Until GVAX delivers definitive and positive Phase III data, other cell therapy companies (like Dendreon and Antigenics) shouldn't get their partnering hopes up.
Advertisement

Related Content

Cancer Vaccine Makers Capitalize On Provenge Fanfare At ASCO
In Immunotherapy, Finally time for T Cells?
For GlobeImmune, Early HCV Vaccine Data May Spark Coveted Partnership
Takeda, Cell Genesys Ink $270 Million GVAX Deal For Prostate Cancer
Takeda/ Millennium: The Price is Right
Stem Cell Summit 2008: Moving from Process to Product
Pharma's New Follow-On Strategy
Gene Therapy: The Next Big Thing?
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
A Look Inside the Provenge Decision: Who's In Charge at FDA?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091564

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel